Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Tianjin University of Traditional Chinese Medicine, Tianjin, China.
BMJ Open. 2019 Aug 30;9(8):e028994. doi: 10.1136/bmjopen-2019-028994.
Patients with lung cancer often experience heavy psychological distress, especially depression, which results in poorer quality of life, shorter survival time and greater mortality. Our aim is to summarise data on the prevalence and risk factors of depression in patients with lung cancer.
We will search PubMed, EMBASE, MEDLINE, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang and Chinese Biomedicine Literature Database (SinoMed) for studies on the prevalence and risk factors of depression in patients with lung cancer, which should be published from 1 January 1975 to 25 November 2018 in English/Chinese. Two reviewers will independently screen studies, extract data and assess the risk of bias. We will use RevMan V.5.0 and STATA V.12.0 software for statistical analysis. The I² test will be used to identify the extent of heterogeneity. Publication bias will be assessed by generating a funnel plot and performing the Begg and Egger test. The quality of the systematic review will be evaluated using the AMSTAR ('A Measurement Tool to Assess Systematic Reviews') criteria and 'The Grading of Recommendations Assessment, Development and Evaluation'.
Since this is a review involving analysis of publicly available data, ethical approval is not required. The final results of this study will be published in a peer-reviewed journal.
CRD42018118167.
肺癌患者常经历严重的心理困扰，尤其是抑郁，这导致生活质量更差、生存时间更短和死亡率更高。我们的目的是总结肺癌患者抑郁的患病率和危险因素的数据。
我们将检索 1975 年 1 月 1 日至 2018 年 11 月 25 日发表的英文/中文的关于肺癌患者抑郁患病率和危险因素的研究，包括 PubMed、EMBASE、MEDLINE、Cochrane 图书馆、Web of Science、中国国家知识基础设施、万方和中国生物医学文献数据库（SinoMed）。两位评审员将独立筛选研究、提取数据并评估偏倚风险。我们将使用 RevMan V.5.0 和 STATA V.12.0 软件进行统计分析。I² 检验用于确定异质性程度。生成漏斗图并进行 Begg 和 Egger 检验来评估发表偏倚。使用 AMSTAR（“系统评价评估工具”）标准和“推荐评估、制定和评估分级”来评估系统评价的质量。
由于这是一项涉及分析公开数据的综述，因此不需要伦理批准。本研究的最终结果将发表在同行评议的期刊上。
PROSPERO 注册号：CRD42018118167。
